Scholarlink

Background <p>Current guidelines make no recommendation regarding appropriate fibrinogen replacement thresholds for non-traumatic massive bleeding. We aimed to determine the optimal post-treatment fibrinogen level associated with survival in critically ill patients with non-traumatic massive bleeding.</p> Methods <p>This multicenter retrospective cohort study enrolled adult ICU patients with non-traumatic massive bleeding and hypofibrinogenemia (fibrinogen &lt;2.0&#xa0;g/L) from 12 centers in China (2018–2025). Maximum fibrinogen level (FIBmax) achieved during treatment within 3 Days of hemorrhage onset was the primary predictor. We used the Boruta algorithm for variable selection, multivariable logistic regression to assess the independent association between FIBmax and hospital mortality, restricted cubic splines to examine dose-response relationships, and pairwise group comparisons with Bonferroni correction to identify the optimal threshold.</p> Results <p>Among 358 patients (median age 59 years; 62.6% male), 74 (20.7%) died during hospitalization. FIBmax was independently associated with hospital mortality after adjustment for confounders (OR 0.37 per g/L increase; 95% CI 0.25–0.57; <i>P</i> &lt; 0.001). Adding FIBmax to the base model significantly improved discrimination (AUC 0.899 vs. 0.868; <i>P</i> = 0.017), calibration (Hosmer-Lemeshow <i>P</i> = 0.096 vs. 0.031), and reclassification (NRI 0.814; IDI 0.076). Restricted cubic spline analysis revealed a non-linear dose-response relationship (P for non-linearity = 0.026), with an inflection point at 2.03&#xa0;g/L. Pairwise comparisons identified a significant hospital mortality transition at 2.0&#xa0;g/L: patients with FIBmax of 1.5–2.0&#xa0;g/L had 3.23-fold higher hospital mortality compared to those achieving 2.0–2.5&#xa0;g/L (<i>P</i> = 0.004), representing the only significant transition point across all adjacent group comparisons. Hospital mortality plateaued at higher levels, with no additional benefit observed above 2.5&#xa0;g/L. Patients achieving FIBmax ≥ 2.0&#xa0;g/L had hospital mortality of 10.1% versus 48.0% for those below this threshold (<i>P</i> &lt; 0.001).</p> Conclusions <p>In critically ill patients with non-traumatic massive bleeding, a post-treatment fibrinogen level of 2.0–2.5&#xa0;g/L appears optimal, and 2.0&#xa0;g/L may represent a potential therapeutic threshold.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimal fibrinogen threshold in non-traumatic massive bleeding: a multicenter retrospective observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月2日

查看全文
  • Siying Chen,
  • Shiyu Liu,
  • Bingkui Ren,
  • Yuping Zhang,
  • Jinglong Dai,
  • Ziyan Ye,
  • Lu Xu,
  • Yun Fan,
  • Chuanbao Li,
  • Zhengying Jiang,
  • Qian Liu,
  • Kang Zou,
  • Zhiyuan Zhang,
  • Wenqing Lian,
  • Shuangling Li,
  • Peng Wang,
  • Lu Ke,
  • Weibang Pan,
  • Wenjian Mao,
  • Feng Guo,
  • Yi-miao Xu,
  • Ting Lin,
  • Wenjun Tan,
  • Weihai Wei,
  • Qiuhua Yang,
  • Jun Duan,
  • Dezhi Ren,
  • Zheng Duan,
  • Luchuan Xing,
  • Hua Xu,
  • Lin Dou,
  • Wensong Su,
  • Linghui Zhan,
  • Fengxue Zhu,
  • Zhigang Chang

摘要

Background

Current guidelines make no recommendation regarding appropriate fibrinogen replacement thresholds for non-traumatic massive bleeding. We aimed to determine the optimal post-treatment fibrinogen level associated with survival in critically ill patients with non-traumatic massive bleeding.

Methods

This multicenter retrospective cohort study enrolled adult ICU patients with non-traumatic massive bleeding and hypofibrinogenemia (fibrinogen <2.0 g/L) from 12 centers in China (2018–2025). Maximum fibrinogen level (FIBmax) achieved during treatment within 3 Days of hemorrhage onset was the primary predictor. We used the Boruta algorithm for variable selection, multivariable logistic regression to assess the independent association between FIBmax and hospital mortality, restricted cubic splines to examine dose-response relationships, and pairwise group comparisons with Bonferroni correction to identify the optimal threshold.

Results

Among 358 patients (median age 59 years; 62.6% male), 74 (20.7%) died during hospitalization. FIBmax was independently associated with hospital mortality after adjustment for confounders (OR 0.37 per g/L increase; 95% CI 0.25–0.57; P < 0.001). Adding FIBmax to the base model significantly improved discrimination (AUC 0.899 vs. 0.868; P = 0.017), calibration (Hosmer-Lemeshow P = 0.096 vs. 0.031), and reclassification (NRI 0.814; IDI 0.076). Restricted cubic spline analysis revealed a non-linear dose-response relationship (P for non-linearity = 0.026), with an inflection point at 2.03 g/L. Pairwise comparisons identified a significant hospital mortality transition at 2.0 g/L: patients with FIBmax of 1.5–2.0 g/L had 3.23-fold higher hospital mortality compared to those achieving 2.0–2.5 g/L (P = 0.004), representing the only significant transition point across all adjacent group comparisons. Hospital mortality plateaued at higher levels, with no additional benefit observed above 2.5 g/L. Patients achieving FIBmax ≥ 2.0 g/L had hospital mortality of 10.1% versus 48.0% for those below this threshold (P < 0.001).

Conclusions

In critically ill patients with non-traumatic massive bleeding, a post-treatment fibrinogen level of 2.0–2.5 g/L appears optimal, and 2.0 g/L may represent a potential therapeutic threshold.